Logo image of RKV.CA

RAKOVINA THERAPEUTICS INC (RKV.CA) Stock Fundamental Analysis

TSX-V:RKV - TSX Venture Exchange - CA75103L1013 - Common Stock - Currency: CAD

0.15  +0.01 (+7.14%)

Fundamental Rating

0

Taking everything into account, RKV scores 0 out of 10 in our fundamental rating. RKV was compared to 0 industry peers in the Unkown industry. RKV has a bad profitability rating. Also its financial health evaluation is rather negative. RKV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year RKV has reported negative net income.
In the past year RKV has reported a negative cash flow from operations.
In the past 5 years RKV always reported negative net income.
In the past 5 years RKV always reported negative operating cash flow.
RKV.CA Yearly Net Income VS EBIT VS OCF VS FCFRKV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

Industry RankSector Rank
ROA -62.38%
ROE -107.71%
ROIC N/A
ROA(3y)-53.37%
ROA(5y)-37.94%
ROE(3y)-60.82%
ROE(5y)-42.7%
ROIC(3y)N/A
ROIC(5y)N/A
RKV.CA Yearly ROA, ROE, ROICRKV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

RKV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RKV.CA Yearly Profit, Operating, Gross MarginsRKV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, RKV has more shares outstanding
The debt/assets ratio for RKV is higher compared to a year ago.
RKV.CA Yearly Shares OutstandingRKV.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
RKV.CA Yearly Total Debt VS Total AssetsRKV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of 0.29, we must say that RKV is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.45 indicates that RKV is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 0.29
ROIC/WACCN/A
WACCN/A
RKV.CA Yearly LT Debt VS Equity VS FCFRKV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

A Current Ratio of 1.43 indicates that RKV should not have too much problems paying its short term obligations.
A Quick Ratio of 1.43 indicates that RKV should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
RKV.CA Yearly Current Assets VS Current LiabilitesRKV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 1M 2M 3M

0

3. Growth

3.1 Past

The earnings per share for RKV have decreased strongly by -20.60% in the last year.
EPS 1Y (TTM)-20.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RKV.CA Yearly Revenue VS EstimatesRKV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023
RKV.CA Yearly EPS VS EstimatesRKV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RKV. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKV.CA Price Earnings VS Forward Price EarningsRKV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKV.CA Per share dataRKV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

RKV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RAKOVINA THERAPEUTICS INC

TSX-V:RKV (3/7/2025, 7:00:00 PM)

0.15

+0.01 (+7.14%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-25 2024-11-25
Earnings (Next)04-25 2025-04-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.16%
Ins Owner ChangeN/A
Market Cap21.12M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.02
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.38%
ROE -107.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.37%
ROA(5y)-37.94%
ROE(3y)-60.82%
ROE(5y)-42.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z 0.29
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.08%
OCF growth 3YN/A
OCF growth 5YN/A